CMC Medical Center (0 mi.)
11100 Euclid Ave
Cleveland, OH 44106
Biography: Marc Pelletier, MD, MS
Certifications & Memberships
- Cardiac Surgery - Royal College of Physicians and Surgeons
Fellowship | Cardiothoracic Transplantation
Cardiothoracic Transplantation - Stanford Hospital And Clinics (2000 - 2001)
Residency | Thoracic Surgery
Thoracic Surgery - Mcgill University Health Centre - The Glen (1994 - 2000)
Mcgill University (2000)
Dalhousie University Faculty Of Medicine (1994)
Marc Pelletier, MD, MSc, FRCSC, is Chief of the Division of Cardiac Surgery at University Hospitals Health System and Director of the Heart Surgery Center for University Hospitals Harrington Heart & Vascular Institute.
Dr. Pelletier joined University Hospitals from Brigham and Women’s Hospital and Harvard Medical School in Boston, where he served since 2016 as surgical director of the transcatheter aortic valve replacement (TAVR) program. Prior to this role, he spent nine years as head of cardiac surgery at the New Brunswick Heart Centre in Canada. Before that, Dr. Pelletier was a surgeon and an assistant professor at Stanford University.
Dr. Pelletier trained at McGill University in cardiac surgery and Stanford University in cardiothoracic transplantation and ventricular assist devices. His areas of specialty include TAVR procedures, minimally invasive valve surgery, aortic valve and aortic root surgery, surgery for heart failure and minimally invasive coronary bypass surgery.
He has authored more than 100 peer-reviewed publications, with over 110 abstracts accepted at scientific meetings and participated in more than 110 invited talks. Dr. Pelletier was chair of the Royal College of Surgeons of Canada’s examination board in cardiac surgery from 2014 to 2018, and in 2018 received the Larry Cohn Outstanding Teacher Award for surgical education. In 2021, he was named one of Cleveland’s Top Doctors and also awarded the Distinguished Surgeon designation at University Hospitals.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Marc Pelletier did not disclose any Outside Relationships with Industry.